Immediate Versus Deferred Androgen Deprivation Therapy,Goserelin for Recurrent Prostate Cancer After Radical Radiotherapy
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicentre, open-labelled, randomized controlled trial comparing the
efficacy of immediate versus deferred androgen deprivation therapy (ADT) using goserelin
(Zoladex®) in men with recurrent prostate cancer after radical radiotherapy.
1100 patients will be accrued from participating Canadian Urological Oncology Group sites in
an estimated time of 3 years. First analysis is planned for 7 years after study recruitment
is completed.